Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

ffer materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)...   Synageva BioPharma Corp. (NASDAQ: ... products for rare disorders, today announced validation by ... Authorization Application (MAA) for sebelipase alfa for LAL ... for accelerated assessment, which has the potential to ... The MAA, and the Biologics License Application ...
(Date:12/24/2014)... CHENGDU, China , Dec. 23, 2014 /PRNewswire/ ... a pharmaceutical company that specializes in patented biopharmaceutical, ... active pharmaceutical ingredients (API) today announced that the ... for its Good Manufacturing Practice (GMP) certificate of ... & Drug Administration,s (CFDA). The public notice period ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... 2012  Verizon Enterprise Solutions, Motorola Mobility Inc. and BoxTone ... help satisfy the unique security, reliability and usability requirements ... practitioners with secure mobile devices and apps, patient care ... in near-real time to help speed decision making and ...
... channels are becoming increasingly plentiful in today,s environment, ... efficient performance, increase profitability and raise consumer loyalty. ... need to identify which external and internal communication ... use them. Best Practices, LLC,s ...
Cached Medicine Technology:Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 2Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 3Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 4Verizon, Motorola Mobility, BoxTone Unveil New Mobile Solution for Health Care Industry 5Effective Communication Options to Increase Organizational Effectiveness 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... Analysis to 2023” focuses on the current treatment ... in the colorectal cancer market. Stivarga is a ... colon or rectal cancer. Boehringer Ingelheim is developing ... the treatment of refractory CRC in the US, ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online ... its collection of discounted prom dresses, most of which ... spokesman of the company, the promotion is valid until ... to expand the UK market. , The prom dresses ... lengths, and styles: A-line strapless, empire strapless chiffon, one ...
(Date:12/25/2014)... FL (PRWEB) December 25, 2014 When head ... find themselves in a frenzy to get rid of it ... But families in Coral Gables now have the solution right ... second salon clinic location, Lice Troopers provides full spectrum head ... the Coral Gable area, including Sunset, Key Biscayne, Brickell, Coconut ...
(Date:12/25/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- Among early ... treatment, less than half of one percent will eventually ... new analysis reveals. The finding comes from a ... between 1998 and 2007, and it suggests that the ... double what experts had previously thought. "The frequency ...
(Date:12/25/2014)... Plugin creators from Pixel Film Studios have ... business presentation tool made specifically for Final Cut ... tool, users can now display their stats and facts ... Studios. “ProFire 5k gives users a multiple options to ... a presentation” , Pixel Film Studios takes the heat ...
Breaking Medicine News(10 mins):Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2
... BD (Becton, Dickinson and Company) (NYSE: BDX ), a global medical technology company, ... , Bank of America and Merrill Lynch 2009 ... 8:40 a.m. EDT, Bernstein,s ... 2009, 9:00 a.m. EDT, ...
... (Nasdaq: WCRX ) announced today that one ... ("Mayne") have filed a second lawsuit against Mylan Pharmaceuticals ... for the District of New Jersey for infringement of ... covers DORYX, a tetracycline-class oral antibiotic. The lawsuit ...
... better understood after taking hands-on approach , , FRIDAY, May ... specific training and tools can help young doctors do ... patients. , Seniors face added challenges with prescriptions, ... one time. Avoiding their greater susceptibility to side effects ...
... Award Honoring the Work of Oncology , NursesSAN ANTONIO, ... CURE magazine,s 2009 Extraordinary Healer Award for Oncology ... during a special reception at the Oncology Nursing Society,s ... patients and caregivers submitted nominations. The winner, Christine ...
... continues; Obama urges calm; global cases total 331 in 11 ... -- The number of confirmed swine flu cases in the ... health officials reported on Friday. , "That,s up eight states ... the U.S. Centers for Disease Control and Prevention,s science ...
... May 1 As the world sits on the ... attempting to reduce the ranks of personnel most skilled ... representing more than 20,000 Registered Nurses in 89 bargaining ... hospitals to reopen contracts regarding wages. In the ...
Cached Medicine News:Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 2Health News:Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent 3Health News:Prescription Training Puts Docs in Shoes of Older Patients 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 2Health News:Winner of 2009 CURE Magazine Extraordinary Healer Award Announced 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 2Health News:Swine Flu Infections Now at 141 in 19 U.S. States 3Health News:Swine Flu Infections Now at 141 in 19 U.S. States 4Health News:Swine Flu Infections Now at 141 in 19 U.S. States 5Health News:Swine Flu Infections Now at 141 in 19 U.S. States 6Health News:Swine Flu Infections Now at 141 in 19 U.S. States 7Health News:Swine Flu Infections Now at 141 in 19 U.S. States 8Health News:Swine Flu Infections Now at 141 in 19 U.S. States 9Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 2Health News:Hospital Staffing Cuts - Pragmatic, Panic or Carefully Planned? 3